ombitasvir

inhibits HCV NS5A protein, component of Viekirax

Also Known As:

ABT-267; ABT267; N,N'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-C,C'-dimethyl ester carbamic acid

Networked: 267 relevant articles (40 outcomes, 77 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pilot-Matias, Tami: 20 articles (03/2019 - 01/2014)
2.	Khatri, Amit: 19 articles (02/2019 - 01/2014)
3.	Menon, Rajeev M: 18 articles (02/2019 - 07/2015)
4.	Cohen, Daniel E: 17 articles (01/2020 - 01/2014)
5.	Zha, Jiuhong: 13 articles (01/2020 - 07/2015)
6.	Dutta, Sandeep: 12 articles (10/2017 - 07/2015)
7.	Redman, Rebecca: 11 articles (03/2019 - 06/2015)
8.	Polepally, Akshanth R: 11 articles (01/2019 - 07/2015)
9.	Poordad, Fred: 10 articles (05/2019 - 01/2014)
10.	Trinh, Roger: 10 articles (01/2019 - 01/2014)

Related Diseases

1.	Infections 09/01/2014 - "Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection." 10/01/2018 - "Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection. " 01/01/2018 - "Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks." 11/01/2017 - "Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis." 09/01/2014 - "In vivo, in combinations with other oral direct acting antivirals, ombitasvir achieves very high rates of sustained virological response (about 95%) in patients with HCV genotype 1 infection with a good tolerability. "
2.	Fibrosis (Cirrhosis) 03/01/2020 - "Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according to updated Summary of Product Characteristics. " 01/01/2018 - "12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis." 04/01/2017 - "Age, sex, and cirrhosis were significant covariates for the AUC values of all the DAAs and body weight was a significant covariate for the AUC values of ombitasvir and dasabuvir. " 01/01/2019 - "This open-label, multicentre, Phase 3 study evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low-dose ribavirin for 12 weeks in genotype 1a-infected patients without cirrhosis. " 01/01/2019 - "Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis."
3.	Chronic Hepatitis C 09/01/2014 - "In conclusion, ombitasvir is a good drug to be used in IFN-free combinations for the treatment of chronic hepatitis C. " 01/01/2019 - "Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate whether these results translate to clinical practice, data were pooled from observational studies across 13 countries. " 02/20/2019 - "Conclusion: In the real world, Ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China has 100% rates of EOT and SVR12 with well- tolerability and safety. " 02/20/2019 - "Objective: To evaluate the real-world safety and curative effect of ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in non-cirrhotic or compensated cirrhotic patients. " 11/01/2018 - "The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin. "
4.	Hepatitis C 12/01/2014 - "Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C." 02/01/2016 - "Managing any treatment-naïve genotype 1 hepatitis C patient with ombitasvir-based therapy is the most economically efficient strategy, although price and efficacy can impact cost-effectiveness. " 12/01/2017 - "Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials." 01/01/2018 - "Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C." 01/01/2017 - "Our results suggest that Ombitasvir, a Hepatitis C NS5B polymerase inhibitor, could be "repurposed" for the control and prevention of beta-tubulin-driven breast cancers. "
5.	Chronic Renal Insufficiency 02/01/2023 - "Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease." 01/01/2017 - "The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. " 01/01/2018 - "Limited data have shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stages 4-5 (<30 mL/min/1.73 m2 ). " 04/01/2019 - "The 3D regimen, a combination of four drugs (ombitasvir, paritaprevir, dasabuvir, and ritonavir), has recently been used for patients with chronic kidney disease infected with genotype 1a and 1b HCV. " 06/01/2018 - "The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). "

Related Drugs and Biologics

1.	paritaprevir
2.	Ritonavir (Norvir)
3.	Ribavirin (Virazole)
4.	dasabuvir
5.	Sofosbuvir
6.	Antiviral Agents (Antivirals)
7.	Interferons
8.	daclatasvir
9.	Simeprevir
10.	Amber

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Aftercare (After-Treatment)
4.	Duration of Therapy
5.	Renal Dialysis (Hemodialysis)